The APOE-ε4 allele is the most prominent genetic risk factor for late onset AD. We will use ApoE4 nanobodies to stabilize the non-pathological conformation of ApoE4, and use photoporation as a means of introducing nanobodies in mammalian cells. In addition, we plan to target nanobodies to the brain in collaboration with prof. Breakefield (Dept. Neurology, Harvard Medical School, Boston).